Home 禄 Business 禄 Manufacturing
Healthcare spending may double
By Feng Jianmin |
April 17, 2013, Wednesday
|
Print Edition
Print Edition
CHINA'S healthcare spending may nearly double in the next three years and pharmaceutical merger and acquisition activities are set to grow in the world's second largest market for such deals, an industry report said yesterday.
By 2015, healthcare expenditure on pharmaceuticals, medical devices, distribution, hospitals, pharmacies and insurance will account for 10 percent of the country's gross domestic product, an increase from nearly 6 percent by the end of 2012, according to the report.
Norbert Meyring, head of KPMG Life Science in China and Asia-Pacific, attributed the increase in spending to robust economic growth, the rising middle class as well as government support, urbanization demand and people's increasing awareness for quality healthcare.
KPMG predicted pharmaceutical M&A activities in China to grow along with the expansion in the market.
Between 2011 and 2012, China registered 132 pharmaceuticals transactions worth US$5.2 billion, surpassing Germany and Japan by both deal number and value, and only lagging the United States as the second largest pharmaceutical M&A market.
By 2015, healthcare expenditure on pharmaceuticals, medical devices, distribution, hospitals, pharmacies and insurance will account for 10 percent of the country's gross domestic product, an increase from nearly 6 percent by the end of 2012, according to the report.
Norbert Meyring, head of KPMG Life Science in China and Asia-Pacific, attributed the increase in spending to robust economic growth, the rising middle class as well as government support, urbanization demand and people's increasing awareness for quality healthcare.
KPMG predicted pharmaceutical M&A activities in China to grow along with the expansion in the market.
Between 2011 and 2012, China registered 132 pharmaceuticals transactions worth US$5.2 billion, surpassing Germany and Japan by both deal number and value, and only lagging the United States as the second largest pharmaceutical M&A market.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
